Activation of Metabotropic Glutamate Receptor 5 Modulates Microglial Reactivity and Neurotoxicity by Inhibiting NADPH Oxidase

Microglia are the resident immune cells of the brain and play a central role in neurodegeneration when they become over-activated, releasing harmful inflammatory mediators. This study investigates the function of the metabotropic glutamate receptor 5 (mGluR5) in microglial activity and its potential as a therapeutic target for neuroinflammatory disorders.

Using both the BV2 microglial cell line and primary rat cortical microglia, the researchers examined the effects of the selective mGluR5 agonist (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) on microglial activation triggered by lipopolysaccharide (LPS) and interferon-gamma (IFN). They employed molecular techniques including siRNA-mediated gene knockdown, Western immunoblotting, and enzyme activity assays to delineate the signaling pathways between mGluR5 activation, NADPH oxidase function, and the subsequent release of neurotoxic factors.

The researchers established that functional mGluR5 receptors are highly expressed on microglia. Treatment with the agonist CHPG significantly reduced the expression of inducible nitric-oxide synthase (iNOS), the production of nitric oxide and tumor necrosis factor-alpha (TNF-alpha), and the generation of reactive oxygen species (ROS). The study demonstrates that mGluR5 activation specifically inhibits the NADPH oxidase complex by decreasing the expression of its essential subunits, p22phox and gp91phox. This inhibition effectively interrupts the inflammatory feedback loop, ultimately protecting neurons from microglial-mediated neurotoxicity.

These results position mGluR5 as a promising target for managing neuroinflammation in conditions such as traumatic brain injury, Alzheimer's disease, and Parkinson's disease. By modulating the microglial response before it causes significant neuronal loss, mGluR5 activation offers a potential strategy for mitigating the chronic progression of various neurodegenerative disorders.